Realm Therapeutics cleared to move its skin disease drug to phase two
February 28, 2017Realm Therapeutics has won FDA’s approval for its IND application to proceed with Phase II clinical trial for its skin disease drug.
According to the company, PR022 is the first candidate in a new class of anti-inflammatory / immunomodulatory topical gels for the treatment of atopic dermatitis (AD), that contains a high, stable concentration of hypochlorous acid.
Realm on Tuesday said it could begin testing in the second half of this year.
Furthermore, according to its analysis, the US market alone in the peak year sales for PR022 could be arouund $1 billion. This includes use of the product for treating patients of all ages with mild-to-moderate disease, the company said in its press release.
Atopic Dermatitis (AD) is a chronic inflammatory skin disease which poses a significant burden on patients’ quality of life and on the overall health care system. AD affects up to 20% of children and up to 3% of adults and prevalence numbers continue to increase.
